Arrowhead Pharmaceuticals, Inc. (ARWR) News
Filter ARWR News Items
ARWR News Results
|Loading, please wait...|
ARWR News Highlights
- ARWR's 30 day story count now stands at 15.
- Over the past 29 days, the trend for ARWR's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- The most mentioned tickers in articles about ARWR are HUGE, RNA and DOW.
Latest ARWR News From Around the Web
Below are the latest news stories about Arrowhead Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARWR as an investment opportunity.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reached full planned enrollment of more than 180 people in the phase 2b trial of ARO-ANG3 to treat patients with mixed dyslipidemia. The study, dubbed ARCHES-2, is expected to be completed around the end 2022 and the company intends to report topline data in H1 2023. Dyslipidemia...
Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia
PASADENA, Calif., February 24, 2022--Arrowhead reached full planned enrollment of more than 180 participants in the Phase 2b ARCHES-2 clinical study of ARO-ANG3 for mixed dyslipidemia
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
PASADENA, Calif., February 18, 2022--Arrowhead Pharmaceuticals doses first subjects in Phase 1/2 Study of ARO-C3, RNAi therapeutic for treatment of complement mediated diseases
PASADENA, Calif., February 17, 2022--Arrowhead presented clinical data on ARO-HIF2 in patients with renal cell carcinoma at 2022 ASCO GU
Some of the best stocks in the market are among the best Russell 2000 stocks to buy.
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update New Pulmonary Programs Announced Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is developing medicines that cause gene silencing using RNA interference (RNAi), a specific means of inhibiting the expression of genes and stopping the production of a specific protein. The company has a deep and diverse pipeline
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), with a price target of $100.00. The company's shares closed last Monday at $52.10, close to its 52-week low of $46.68. According to TipRanks.com, Trucchio has 0 stars on 0-5 stars ranking scale with an average return of -17.3% and a 29.1% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Milestone Pharmaceuticals, and Precision BioSciences. Arrowhead Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $83.00, a 67.1% upside from current levels.
Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Dr. Christopher Anzalone on Q1 2022 Results - Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2022 Results Conference Call February 02, 2022 04:30 PM ET Company Participants Vince Anzalone - VP, IR Dr. Christopher Anzalone - President and CEO Dr. Javier San Martin - Chief Medical Officer Ken Myszkowski - CFO Dr. James Hamilton - SVP, Discovery and Translational Medicine...
Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) are down 4% in after-hours trading amid a significant miss on EPS in its FQ1 2022 results and a huge miss on revenue. The company reported GAAP EPS in the quarter of -$0.60, a $0.20 miss. Revenue of $27.4M missed by $23.6M. Arrowhead was hampered in the...
Arrowhead Pharmaceuticals press release (NASDAQ:ARWR): Q1 GAAP EPS of -$0.60 misses by $0.20. Revenue of $27.4M (+28.6% Y/Y) misses by $23.64M....